Research ArticleOpen AccessGoogle Scholar indexed
Successful Treatment of Elderly Diffuse Large B-Cell Lymphoma with Central Nervous System Recurrence by Rituximab, Ranimusutine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy
Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
Division of Pathology, National Hospital Organization Disaster Medical Center, Japan
Division of Pathology, National Hospital Organization Disaster Medical Center, Japan
Division of Radiology, National Hospital Organization Disaster Medical Center, Japan
Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
Division of Pathology, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan
Division of Pathology, National Hospital Organization Disaster Medical Center, Japan
Hematology Division, National Center for Global Health and Medicine, Japan
Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
- 1 Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
- 2 Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
- 3 Division of Pathology, National Hospital Organization Disaster Medical Center, Japan
- 4 Division of Pathology, National Hospital Organization Disaster Medical Center, Japan
- 5 Division of Radiology, National Hospital Organization Disaster Medical Center, Japan
- 6 Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
- 7 Division of Pathology, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan
- 8 Division of Pathology, National Hospital Organization Disaster Medical Center, Japan
- 9 Hematology Division, National Center for Global Health and Medicine, Japan
- 10 Division of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
Journal of Cancer Therapy·Volume 04 (2013)·Pages 448–451·Published 7 March 2013·DOI10.4236/jct.2013.43A054
Copy link · social · email
Abstract
The prognosis of CD20-positive (CD20+) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) recurrence is still poor. A standard treatment for CD20+ DLBCL with CNS recurrence in elderly patients has not been established mainly due to adverse effects. We previously reported the efficacy and safety of MIND-E (ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide) therapy for elderly CD20+ DLBCL patients with CNS recur rence. Here, we report the use of R-MIND-E therapy (rituximab, ranimustine, ifosfamide, procarbazine, dexamethasone and etoposide) in an elderly CD20+ DLBCL patient with CNS recurrence. The patient achieved a complete response according to Revised Response Criteria for Malignant Lymphoma , and treatment-related toxicity was tolerable. R-MIND-E therapy may be a feasible and useful treatment option for elderly CD20+ DLBCL patients with CNS recur rence.
KeywordsDiffuse Large B-Cell LymphomaCentral Nervous System RecurrenceRituximabMIND-E
- B. Coiffier, E. Lepage, J. Briere, et al., “CHOP Chemotherapy Plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large B Cell Lymphoma,” New England Journal of Medicine, Vol. 346, No. 4, 2002, pp. 235-242. doi:10.1056/NEJMoa011795
- W. M. Tai, J. Chung, P. L. Tang, et al., “Central Nervous System (CNS) Relapse in Diffuse Large B Cell Lymphoma (DLBCL): Preand Post-Rituximab,” Annals of Hematology, Vol. 90, No. 7, 2011, pp. 809-818. doi:10.1007/s00277-010-1150-7
- A. Miwa, N. Sekiguchi, A. Tanimura, et al., “Ranimustine, Ifosfamide, Procarbazine, Dexamethasone, and Etoposide Therapy for Central Nervous System Recurrence of Diffuse Large B-Cell Lymphoma in Patients with Poor Performance Status: A Pilot Study,” Leukemia and Lymphoma, Vol. 52, No. 10, 2011, pp. 1898-1903. doi:10.3109/10428194.2011.588759
- G. D. Shah, J. Yahalom, D. D. Correa, et al., “Combined Immunochemotherapy with Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma,” Journal of Clinical Oncology, Vol. 25, No. 30, 2007, pp. 4730-4735. doi:10.1200/JCO.2007.12.5062
- R. C. Curry, D. Correa, J. J. Raizer, et al., “Consolidation Reduced Dose Whole Brain Radiotherapy (rdWBRT) Following Methotrexate, Rituximab, Procarbazine, Vincristine, Cytarabine (R-MPV-A) for Newly Diagnosed Primary CNS Lymphoma (PCNSL): Final Results and Long-Term Outcome,” Journal of Clinical Oncology, Vol. 30, No. 15, 2012, p. 2006.
- T. Bimbaum, E. A. Stadler, L. V. Baumgarten and A. Straube, “Rituximab Significantly Improves Complete Response Rate in Patients with Primary CNS Lymphoma,” Journal of Neurooncology, Vol. 109, No. 2, 2012, pp. 285-291. doi:10.1007/s11060-012-0891-7
- M. J. Wieduwilt, F. Valles, S. Issa, et al., “Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI,” Clincal Cancer Research, Vol. 18, No. 4, 2012, pp. 1146-1155. doi:10.1158/1078-0432.CCR-11-0625
- B. D. Cheson, B. Pfistner, M. E. Juweid, et al., “Revised Response Criteria for Malignant Lymphoma,” Journal of Clinical Oncology, Vol. 25, No. 5, 2007, pp. 579-586. doi:10.1200/JCO.2006.09.2403
- D. Villa, J. M. Connors, T. N. Shenkier, et al., “Incidence and Risk Factors for Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma: The Impact of the Addition of Rituximab to CHOP Chemotherapy,” Annals of Oncology, Vol. 21, No. 5, 2010, pp. 1046-1052. doi:10.1093/annonc/mdp432